Annual EBITDA
-$433.31 M
+$181.60 M+29.53%
December 31, 2023
Summary
- As of February 7, 2025, GH annual EBITDA is -$433.31 million, with the most recent change of +$181.60 million (+29.53%) on December 31, 2023.
- During the last 3 years, GH annual EBITDA has fallen by -$208.23 million (-92.52%).
- GH annual EBITDA is now -999.15% below its all-time high of -$39.42 million, reached on December 31, 2016.
Performance
GH EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$96.48 M
-$5.25 M-5.76%
September 30, 2024
Summary
- As of February 7, 2025, GH quarterly EBITDA is -$96.48 million, with the most recent change of -$5.25 million (-5.76%) on September 30, 2024.
- Over the past year, GH quarterly EBITDA has dropped by -$22.55 million (-30.50%).
- GH quarterly EBITDA is now -1004.90% below its all-time high of -$8.73 million, reached on June 30, 2019.
Performance
GH Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$467.00 M
-$22.55 M-5.07%
September 30, 2024
Summary
- As of February 7, 2025, GH TTM EBITDA is -$467.00 million, with the most recent change of -$22.55 million (-5.07%) on September 30, 2024.
- Over the past year, GH TTM EBITDA has dropped by -$81.25 million (-21.06%).
- GH TTM EBITDA is now -1632.97% below its all-time high of -$26.95 million, reached on September 30, 2017.
Performance
GH TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
GH EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +29.5% | -30.5% | -21.1% |
| 3 y3 years | -92.5% | +24.9% | +24.1% |
| 5 y5 years | -471.4% | +24.9% | +24.1% |
GH EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -20.5% | +29.5% | -58.2% | +56.1% | -29.9% | +24.9% |
| 5 y | 5-year | -658.4% | +29.5% | -412.4% | +56.1% | -717.4% | +24.9% |
| alltime | all time | -999.1% | +29.5% | -1004.9% | +56.1% | -1633.0% | +24.9% |
Guardant Health EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$96.48 M(+5.8%) | -$467.00 M(+5.1%) |
| Jun 2024 | - | -$91.23 M(-11.6%) | -$444.45 M(+7.3%) |
| Mar 2024 | - | -$103.22 M(-41.4%) | -$414.22 M(-4.4%) |
| Dec 2023 | -$433.31 M(-29.5%) | -$176.07 M(+138.2%) | -$433.31 M(+12.3%) |
| Sep 2023 | - | -$73.93 M(+21.2%) | -$385.75 M(-16.7%) |
| Jun 2023 | - | -$61.00 M(-50.1%) | -$463.25 M(-25.5%) |
| Mar 2023 | - | -$122.30 M(-4.8%) | -$621.81 M(+1.1%) |
| Dec 2022 | -$614.91 M(+71.0%) | -$128.52 M(-15.1%) | -$614.91 M(+11.4%) |
| Sep 2022 | - | -$151.43 M(-31.0%) | -$551.96 M(+10.0%) |
| Jun 2022 | - | -$219.56 M(+90.2%) | -$501.77 M(+34.4%) |
| Mar 2022 | - | -$115.41 M(+76.0%) | -$373.44 M(+3.8%) |
| Dec 2021 | -$359.62 M(+59.8%) | -$65.57 M(-35.2%) | -$359.62 M(-4.7%) |
| Sep 2021 | - | -$101.24 M(+11.0%) | -$377.50 M(+9.9%) |
| Jun 2021 | - | -$91.22 M(-10.2%) | -$343.50 M(+15.2%) |
| Mar 2021 | - | -$101.59 M(+21.8%) | -$298.17 M(+32.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2020 | -$225.07 M(+294.0%) | -$83.44 M(+24.1%) | -$225.07 M(+40.3%) |
| Sep 2020 | - | -$67.24 M(+46.5%) | -$160.46 M(+52.9%) |
| Jun 2020 | - | -$45.89 M(+61.0%) | -$104.91 M(+54.8%) |
| Mar 2020 | - | -$28.50 M(+51.3%) | -$67.75 M(+18.6%) |
| Dec 2019 | -$57.13 M(-24.7%) | -$18.83 M(+61.0%) | -$57.13 M(-6.4%) |
| Sep 2019 | - | -$11.69 M(+33.9%) | -$61.07 M(-13.5%) |
| Jun 2019 | - | -$8.73 M(-51.2%) | -$70.58 M(-13.5%) |
| Mar 2019 | - | -$17.88 M(-21.5%) | -$81.60 M(+7.6%) |
| Dec 2018 | -$75.84 M(+0.7%) | -$22.77 M(+7.4%) | -$75.84 M(+14.2%) |
| Sep 2018 | - | -$21.20 M(+7.3%) | -$66.43 M(-8.0%) |
| Jun 2018 | - | -$19.75 M(+63.0%) | -$72.17 M(+37.7%) |
| Mar 2018 | - | -$12.12 M(-9.3%) | -$52.42 M(+30.1%) |
| Dec 2017 | -$75.31 M(+91.0%) | -$13.36 M(-50.4%) | -$40.30 M(+49.6%) |
| Sep 2017 | - | -$26.95 M | -$26.95 M |
| Dec 2016 | -$39.42 M | - | - |
FAQ
- What is Guardant Health annual EBITDA?
- What is the all time high annual EBITDA for Guardant Health?
- What is Guardant Health annual EBITDA year-on-year change?
- What is Guardant Health quarterly EBITDA?
- What is the all time high quarterly EBITDA for Guardant Health?
- What is Guardant Health quarterly EBITDA year-on-year change?
- What is Guardant Health TTM EBITDA?
- What is the all time high TTM EBITDA for Guardant Health?
- What is Guardant Health TTM EBITDA year-on-year change?
What is Guardant Health annual EBITDA?
The current annual EBITDA of GH is -$433.31 M
What is the all time high annual EBITDA for Guardant Health?
Guardant Health all-time high annual EBITDA is -$39.42 M
What is Guardant Health annual EBITDA year-on-year change?
Over the past year, GH annual EBITDA has changed by +$181.60 M (+29.53%)
What is Guardant Health quarterly EBITDA?
The current quarterly EBITDA of GH is -$96.48 M
What is the all time high quarterly EBITDA for Guardant Health?
Guardant Health all-time high quarterly EBITDA is -$8.73 M
What is Guardant Health quarterly EBITDA year-on-year change?
Over the past year, GH quarterly EBITDA has changed by -$22.55 M (-30.50%)
What is Guardant Health TTM EBITDA?
The current TTM EBITDA of GH is -$467.00 M
What is the all time high TTM EBITDA for Guardant Health?
Guardant Health all-time high TTM EBITDA is -$26.95 M
What is Guardant Health TTM EBITDA year-on-year change?
Over the past year, GH TTM EBITDA has changed by -$81.25 M (-21.06%)